Anti-MEGF9 Antibody Picoband®

Overview

Anti-MEGF9 Antibody Picoband® is an antibody reagent for detection of MEGF9 (kelch repeat and BTB domain containing 2). Researchers commonly use anti-MEGF9 antibodies to measure relative expression and localization across biological samples, with assay selection guided by the listed applications (WB, IHC, Flow, ELISA).

Boster Bio Anti-MEGF9 Antibody Picoband® catalog # A15544-2. Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: MEGF9 — Transmembrane protein 240 (kelch repeat and BTB domain containing 2). Alternative names: Kelch repeat and BTB domain-containing protein 2; BTB and kelch domain-containing protein 1; KBTBD2; BKLHD1; KIAA1489
• Antibody format: Polyclonal; Rabbit IgG
• Species context: Host: Rabbit, Reactivity: Human
• Purification: Immunogen affinity purified.
• Immunogen: E.coli-derived human MEGF9 recombinant protein (Position: R216-N468).
• Molecular weight context: observed 63 kDa, calculated 24145 MW (reported)
• Provided application(s): WB, IHC, Flow, ELISA

These attributes help contextualize how the antibody is commonly selected (host/clonality/isotype/label) and how signals are interpreted across sample types and assay formats.

Biological background

Function: Required for DNA double-strand breaks (DSBs) formation in unsynapsed regions during meiotic recombination. Probably acts by forming a complex with MEI4 and REC114, which activates DSBs formation in unsynapsed regions, an essential step to ensure completion of synapsis. Not required for HORMAD1 functions in pairing-independent synaptonemal complex formation, ATR recruitment to unsynapsed axes, meiotic silencing of unsynapsed chromatin (MSUC) or meiotic surveillance.

Cellular localization: Cul3-RING ubiquitin ligase complex.

Tissue details: Detected in liver, skeletal muscle, kidney, pancreas, spleen, thyroid, testis, ovary, small intestine and colon.

Background: MEGF9 (Multiple EGF?like domains protein 9; also EGF?like protein 5) is a 63 kDa (predicted) novel transmembrane glycoprotein that shares some homology to beta ?chains of laminin. It is expressed by hepatocytes, cerebellar Purkinje cells, Schwann cells, keratinocytes and intestinal epithelium. MEGF9 is suggested to participate in cell motility, and its absence correlates with tumor cell migration. Mature human MEGF9 is 572 amino acids (aa) in length. It is a single span type I transmembrane protein that contains a 484 aa extracellular region (aa 31?514) plus a 68 aa C?terminal cytoplasmic domain. The extracellular region possesses a lengthy Pro?rich region (aa 55?200), followed by five EGF?like domains (aa 204?451). MEGF9 may run at approximately 160 kDa in SDS?PAGE, suggesting either heavy glycosylation or dimerization. Over aa 36?514, human MEGF9 shares 76% aa sequence identity with mouse MEGF9.

Cross reactivity: No cross-reactivity with other proteins.

Research relevance and current trends

• Quantitative and spatial profiling: expression patterns are increasingly studied across cell states using multiplex imaging and omics-informed validation.
• Isoforms and post-translational modifications: researchers often evaluate how isoform composition and PTMs can shift apparent molecular weight or localization.
• Context-aware interpretation: comparative studies commonly include perturbations (stimulation, inhibition, genetic models) to relate target changes to pathway behavior.

Common research applications

• Western blot (WB): compare relative target abundance and apparent size shifts (e.g., isoforms/PTMs) across conditions.
• Immunohistochemistry (IHC): assess distribution across tissue compartments and compare staining patterns between groups.
• Flow cytometry: quantify target-positive populations and compare shifts after stimulation or differentiation.

Across these uses, researchers typically interpret changes in signal as relative differences between matched sample groups, considering sample preparation and biological context.

Notes for experimental interpretation

• Apparent molecular weight can vary due to isoforms, proteolysis, glycosylation, phosphorylation, and sample preparation differences.
• Species reactivity and epitope conservation can influence observed signal patterns, especially in cross-species studies.
• Control concepts: include appropriate negative controls (e.g., isotype controls where relevant) and, when feasible, genetic or orthogonal controls (KO/KD, peptide competition, or independent assays) to support interpretation.

For antibody reagents, monoclonal antibodies are often chosen for epitope consistency across lots, while polyclonals may recognize multiple epitopes and can show different background characteristics depending on context.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.